164 related articles for article (PubMed ID: 12498733)
1. Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PK1, and OK.
Endo T; Kimura O; Sakata M
Toxicol Appl Pharmacol; 2002 Dec; 185(3):166-71. PubMed ID: 12498733
[TBL] [Abstract][Full Text] [Related]
2. Effects of P-glycoprotein inhibitors on transepithelial transport of cadmium in cultured renal epithelial cells, LLC-PK1 and LLC-GA5-COL 150.
Kimura O; Endo T; Hotta Y; Sakata M
Toxicology; 2005 Mar; 208(1):123-32. PubMed ID: 15664439
[TBL] [Abstract][Full Text] [Related]
3. Outward transfer of dopamine precursor L-3,4-dihydroxyphenylalanine (L-dopa) by native and human P-glycoprotein in LLC-PK(1) and LLC-GA5 col300 renal cells.
Soares-Da-Silva P; Serrão MP
J Pharmacol Exp Ther; 2000 May; 293(2):697-704. PubMed ID: 10773046
[TBL] [Abstract][Full Text] [Related]
4. Interaction of docetaxel ("Taxotere") with human P-glycoprotein.
Shirakawa K; Takara K; Tanigawara Y; Aoyama N; Kasuga M; Komada F; Sakaeda T; Okumura K
Jpn J Cancer Res; 1999 Dec; 90(12):1380-6. PubMed ID: 10665657
[TBL] [Abstract][Full Text] [Related]
5. In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil.
Higashi H; Watanabe N; Tamura R; Taguchi M
Biol Pharm Bull; 2017; 40(8):1314-1319. PubMed ID: 28769012
[TBL] [Abstract][Full Text] [Related]
6. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD
Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
[TBL] [Abstract][Full Text] [Related]
7. Effects of Kaempferia parviflora extracts and their flavone constituents on P-glycoprotein function.
Patanasethanont D; Nagai J; Yumoto R; Murakami T; Sutthanut K; Sripanidkulchai BO; Yenjai C; Takano M
J Pharm Sci; 2007 Jan; 96(1):223-33. PubMed ID: 17031860
[TBL] [Abstract][Full Text] [Related]
8. The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein.
Takara K; Tanigawara Y; Komada F; Nishiguchi K; Sakaeda T; Okumura K
Jpn J Cancer Res; 2000 Feb; 91(2):248-54. PubMed ID: 10761713
[TBL] [Abstract][Full Text] [Related]
9. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.
Ito T; Yano I; Tanaka K; Inui KI
J Pharmacol Exp Ther; 1997 Aug; 282(2):955-60. PubMed ID: 9262363
[TBL] [Abstract][Full Text] [Related]
10. Directional transcellular transport of bisoprolol in P-glycoprotein-expressed LLC-GA5-COL150 cells, but not in renal epithelial LLC-PK1 Cells.
Tahara K; Kagawa Y; Takaai M; Taguchi M; Hashimoto Y
Drug Metab Pharmacokinet; 2008; 23(5):340-6. PubMed ID: 18974611
[TBL] [Abstract][Full Text] [Related]
11. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs.
Takara K; Tanigawara Y; Komada F; Nishiguchi K; Sakaeda T; Okumura K
Biol Pharm Bull; 1999 Dec; 22(12):1355-9. PubMed ID: 10746169
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the involvement of P-glycoprotein on the extrusion of taken up L-DOPA in cyclosporine A treated LLC-PK1 cells.
Soares-da-Silva P; Serrão MP; Vieira-Coelho MA; Pestana M
Br J Pharmacol; 1998 Jan; 123(1):13-22. PubMed ID: 9484849
[TBL] [Abstract][Full Text] [Related]
13. Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene.
Tanaka K; Hirai M; Tanigawara Y; Ueda K; Takano M; Hori R; Inui K
Biochem Pharmacol; 1997 Mar; 53(5):741-6. PubMed ID: 9113094
[TBL] [Abstract][Full Text] [Related]
14. Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil.
Kakumoto M; Sakaeda T; Takara K; Nakamura T; Kita T; Yagami T; Kobayashi H; Okamura N; Okumura K
Cancer Sci; 2003 Jan; 94(1):81-6. PubMed ID: 12708479
[TBL] [Abstract][Full Text] [Related]
15. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
Matsuzaki J; Yamamoto C; Miyama T; Takanaga H; Matsuo H; Ishizuka H; Kawahara Y; Kuwano M; Naito M; Tsuruo T; Sawada Y
Biopharm Drug Dispos; 1999 Mar; 20(2):85-90. PubMed ID: 10206323
[TBL] [Abstract][Full Text] [Related]
16. Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment.
Jetté L; Murphy GF; Béliveau R
Int J Cancer; 1998 May; 76(5):729-37. PubMed ID: 9610733
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal absorption of pimozide is enhanced by inhibition of P-glycoprotein.
Morishita H; Okawa K; Ishii M; Mizoi K; Ito MA; Arakawa H; Yano K; Ogihara T
PLoS One; 2020; 15(10):e0232438. PubMed ID: 33119612
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of doxorubicin handling in the LLC-PK1 kidney epithelial cell line is mediated by both vesicle formation and P-glycoprotein drug transport.
Crivellato E; Candussio L; Rosati AM; Decorti G; Klugmann FB; Mallardi F
Histochem J; 1999 Oct; 31(10):635-43. PubMed ID: 10576412
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of ecto-5'-nucleotidase promotes P-glycoprotein expression in renal epithelial cells.
Ledoux S; Leroy C; Siegfried G; Prie D; Moullier P; Friedlander G
Kidney Int; 1997 Oct; 52(4):953-61. PubMed ID: 9328934
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.
Kusunoki N; Takara K; Tanigawara Y; Yamauchi A; Ueda K; Komada F; Ku Y; Kuroda Y; Saitoh Y; Okumura K
Jpn J Cancer Res; 1998 Nov; 89(11):1220-8. PubMed ID: 9914792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
